Cardlytics (CDLX) Research & Development (2017 - 2026)
Cardlytics filings provide 10 years of Research & Development readings, the most recent being $6.4 million for Q1 2026.
- Quarterly Research & Development fell 37.44% to $6.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $34.5 million through Mar 2026, down 26.36% year-over-year, with the annual reading at $39.8 million for FY2025, 19.84% down from the prior year.
- Research & Development hit $6.4 million in Q1 2026 for Cardlytics, down from $8.0 million in the prior quarter.
- Across five years, Research & Development topped out at $14.8 million in Q2 2023 and bottomed at $6.4 million in Q1 2026.
- Average Research & Development over 5 years is $11.8 million, with a median of $12.4 million recorded in 2023.
- The largest annual shift saw Research & Development soared 97.67% in 2022 before it tumbled 37.44% in 2026.
- Cardlytics' Research & Development stood at $14.8 million in 2022, then dropped by 15.47% to $12.5 million in 2023, then dropped by 20.91% to $9.9 million in 2024, then decreased by 19.5% to $8.0 million in 2025, then decreased by 19.27% to $6.4 million in 2026.
- Per Business Quant, the three most recent readings for CDLX's Research & Development are $6.4 million (Q1 2026), $8.0 million (Q4 2025), and $8.8 million (Q3 2025).